Compare AGMB & MG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGMB | MG |
|---|---|---|
| Founded | 2017 | 1978 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.2M | 642.4M |
| IPO Year | 2024 | 2008 |
| Metric | AGMB | MG |
|---|---|---|
| Price | $5.54 | $20.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $37.67 | $21.18 |
| AVG Volume (30 Days) | 297.3K | ★ 356.5K |
| Earning Date | 12-01-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.51 |
| Revenue | N/A | ★ $700,970,000.00 |
| Revenue This Year | N/A | $3.15 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $39.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $11.15 |
| 52 Week High | $17.82 | $21.92 |
| Indicator | AGMB | MG |
|---|---|---|
| Relative Strength Index (RSI) | 23.66 | 43.99 |
| Support Level | N/A | $20.06 |
| Resistance Level | $9.55 | $21.77 |
| Average True Range (ATR) | 0.69 | 0.06 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 5.17 | 43.33 |
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International, and Products and Systems, of which key revenue is derived from the North America segment. The North America segment provides asset protection solutions, including NDT, inspection, and mechanical and engineering services, along with software, digital, and data services.